PTPRD and cancer: In TCGA pan-cancer cohort, survival analysis showed that the OS was worse in patients with PTPRD/PTPRT mutations than in the WT (mOS, 65.52 vs 81.11 months, HR = 1.119, 95%CI: 1.018-1.228; P = 0.014) (Figure 3A).